Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Leases (2019 - 2023)

Historic Current Leases for Spyre Therapeutics (SYRE) over the last 5 years, with Q2 2023 value amounting to $4.3 million.

  • Spyre Therapeutics' Current Leases rose 80796.65% to $4.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $4.3 million, marking a year-over-year increase of 80796.65%. This contributed to the annual value of $625000.0 for FY2022, which is 4334.86% up from last year.
  • As of Q2 2023, Spyre Therapeutics' Current Leases stood at $4.3 million, which was up 80796.65% from $608000.0 recorded in Q1 2023.
  • Spyre Therapeutics' 5-year Current Leases high stood at $4.3 million for Q2 2023, and its period low was $228000.0 during Q2 2020.
  • Its 5-year average for Current Leases is $618277.8, with a median of $381500.0 in 2019.
  • As far as peak fluctuations go, Spyre Therapeutics' Current Leases tumbled by 3048.78% in 2020, and later skyrocketed by 80796.65% in 2023.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Current Leases stood at $351000.0 in 2019, then fell by 9.12% to $319000.0 in 2020, then soared by 36.68% to $436000.0 in 2021, then soared by 43.35% to $625000.0 in 2022, then skyrocketed by 592.96% to $4.3 million in 2023.
  • Its Current Leases was $4.3 million in Q2 2023, compared to $608000.0 in Q1 2023 and $625000.0 in Q4 2022.